Treats major depressive disorder (MDD). ANDA 205468, held by MPP Pharma. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 205468 (Venlafaxine Hydrochloride), held by MPP Pharma, was first approved by FDA on Mar 24, 2017, with 0 approved supplements and 0 published complete response letters.
Venlafaxine hydrochloride extended-release tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) Social Anxiety Disorder (SAD) 1.1 Major Depressive Disorder Venlafaxine hydrochloride extended-release tablets are indicated for the treatment of major depressive disorder (MDD). Efficacy of venlafaxine in MDD was shown in both short-term trials and a longer-term trial in MDD.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 24, 2017 | Original application | Approved |
| Venlafaxine HydrochlorideEQ 150MG BASE · tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 225MG BASE · tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters